All News
Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhances the identification of axial spondyloarthritis. With 14.3% of positive screenings leading to diagnosis.
Another innovation that may help with the rapid… https://t.co/qSwryK22uj
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#0456📱 Digital Health & RA ePROs
💻Rx response in 150 RA patients using ePROs & actigraphy
🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone)
💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden.
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure:
-Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie
#ACR24 @RheumNow https://t.co/Jc0cdmrVhI
Adela Castro AdelaCastro222 ( View Tweet)
Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk.
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39
Akhil Sood MD AkhilSoodMD ( View Tweet)
TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW https://t.co/MjzE14SeGi
Links:
Richard Conway RichardPAConway ( View Tweet)
Happening now:
16S18 Into the Weeds: Cannabis in Rheum
@EleniTiniakou @BharatKumarMD
Do you discuss marijuana with your patients?
@RheumNow #ACR24
Eric Dein ericdeinmd ( View Tweet)
Ashgar et al. Metformin reduces risk of TKR in T2DM with OA in meta-analysis. RR 0.59 @RheumNow #ACR24 Abstr#0029 https://t.co/OhqTJZQwKX https://t.co/RTQUjE6lLy
Links:
Richard Conway RichardPAConway ( View Tweet)
Abstr#0647
Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & renal involvement. Linked to younger age, White race, +SSB, & lower ACR/EULAR scores
- Tx: GC, HCQ, AZA
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract #0614
What is the impact of Lupus on my quality of life?
Consider using Lupus Impact Tracker (https://t.co/fJQe2uHicM)
- high dose GC, comorbidities, and not actively working associated with worse impact on QoL
- HCQ shows benefit
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
#0477 🌍 Global prevalence of RA-ILD
➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281
🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use.
⛔️Wide CI = heterogeneity main limitation
💡 Screening & lifestyle changes key for high-risk groups.
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Harnessing power of AI in Rheumatology. Strengths and weaknesses of AI will need to be assessed. Amanda Nelson shares the limitation of AI @RheumNow #ACR24 https://t.co/G8FNVco7Qp
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including: - Higher BMI - Increased comorbidities - Presence of EAMs - HLA-B27 positivity is linked to higher odds of being D2T, highlighting potential genetic… https://t.co/XcShdxSwhm
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Data from the EISER study show that IBD was significantly more prevalent in pts with r-axSpA than nr-axSpA.
Makes sense in a way since longer dse duration may play a role.
🔶️THM - screen SpA pts for IBD; ask for GI symptoms
@RheumNow #ACR24 abs554 https://t.co/Q6jeDUFa8Z
sheila RHEUMarampa ( View Tweet)
High PBO effect in PsA studies
Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12:
💡PBO rates significantly increased over time.
💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe
Adela Castro AdelaCastro222 ( View Tweet)
Lots of ‘CARTS’, not enough ‘work horses’!
There are now ~40 CAR-T protocols in #lupus incl many presentations at #ACR24
-most are uncontrolled
-selection of pts is key.
We need a pathway forward for reg approval & guidelines for studies!
@RheumNow @ACRheum 18abst #OOO4 https://t.co/Mckwvn3Ffn
Janet Pope Janetbirdope ( View Tweet)
#0582🔬Challenges in Achieving PsA Disease Control
➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively
🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes.
🩺Unmet needs remain in PsA; tailored Rx needed
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis
Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction?
#ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW
Links:
Mike Putman EBRheum ( View Tweet)
Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335)
Risk high among Class III, IV, V and eGFR > 30
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
#0501
💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA
➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers
🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised
💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)